德谷胰岛素利拉鲁肽在超重/肥胖T2DM患者中的应用效果OA
Application Effect of Insulin Degludec and Liraglutide in Overweight/Obese Patients with T2DM
目的:观察采用德谷胰岛素利拉鲁肽治疗超重/肥胖 2 型糖尿病(T2DM)患者的效果.方法:选取 2024 年 4 月—2025 年 5 月于上饶市立医院治疗的超重/肥胖 T2DM 患者 80 例,随机分为对照组与研究组.两组均采用二甲双胍治疗,对照组(n=40)增加甘精胰岛素治疗,研究组(n=40)增加德谷胰岛素利拉鲁肽注射液治疗,均治疗 3 个月.观察比较两组疗效、血糖控制效果、胰岛素抵抗情况及减重效果.结果:研究组治疗总有效率为 92.50%,较对照组的 67.50%高(P<0.05).治疗后,两组糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后 2 h 血糖(2 h PG)水平较治疗前下降,研究组各指标水平较对照组低(P<0.05).治疗后,两组稳态模型胰岛素抵抗指数(HOMA-IR)、空腹胰岛素(FINS)较治疗前下降,稳态模型胰岛 β 细胞功能指数(HOMA-β)较治疗前升高,相比对照组,研究组 FINS、HOMA-IR 低,HOMA-β 高(P<0.05).治疗后,两组体重、腰围与 BMI 较治疗前下降,脂联素较治疗前升高,研究组体重、腰围与BMI低于对照组,脂联素高于对照组(P<0.05).结论:德谷胰岛素利拉鲁肽治疗超重/肥胖 T2DM 相较甘精胰岛素的效果更好,能有效控制血糖,改善胰岛素抵抗,并有一定的减重效果.
Objective:To observe the effect of Insulin Degludec and Liraglutide in treating overweight/obese patients with type 2 diabetes mellitus(T2DM).Method:Eighty overweight/obese patients with T2DM who were treated in Shangrao Municipal Hospital from April 2024 to May 2025 were selected,and randomly divided into the control group and the study group.Both groups were treated with Metformin Hydrochloride.The control group(n=40)was additionally treated with Insulin Glargine,and the study group(n=40)was additionally treated with Insulin Degludec and Liraglutide Injection.Both groups were treated for 3 months.The therapeutic effect,blood glucose control effect,insulin resistance conditions,and weight loss effect of the two groups were observed and compared.Result:The total effective rate of the study group was 92.50%,which was higher than 67.50%of the control group(P<0.05).After treatment,glycosylated hemoglobin(HbA1c),fasting plasma glucose(FPG)and 2-hour postprandial plasma glucose(2 h PG)levels were all decreased in both groups compared with those before treatment,the levels of each indicator were significantly lower in the study group compared with the control group(P<0.05).After treatment,the homeostatic model assessment of insulin resistance(HOMA-IR)and fasting insulin(FINS)in both groups decreased compared to before treatment,while homeostatic model assessment of β cell function(HOMA-β)increased compared to before treatment,compared with the control group,the FINS and HOMA-IR in the study group were lower,and HOMA-β was higher(P<0.05).After the treatment,the weight,waist circumference and BMI of both groups decreased compared to before the treatment,while adiponectin increased compared to before the treatment,the weight,waist circumference and BMI of the study group were lower than those of the control group,and adiponectin was higher than that of the control group(P<0.05).Conclusion:Compared to Insulin Glargine,Insulin Degludec and Liraglutide is more effective to treat overweight/obese patients with T2DM,it can effectively control blood glucose,improve insulin resistance,and have a certain weight loss effect.
李慧岚;何美玲;张玥
上饶市立医院内分泌科 江西 上饶 334000上饶市立医院内分泌科 江西 上饶 334000上饶市立医院内分泌科 江西 上饶 334000
医药卫生
超重/肥胖2型糖尿病德谷胰岛素利拉鲁肽甘精胰岛素血糖胰岛素抵抗
Overweight/obeseType 2 diabetes mellitusInsulin Degludec and LiraglutideInsulin GlargineBlood glucoseInsulin resistance
《中国医学创新》 2026 (22)
107-111,5
上饶市科技计划医疗卫生指导项目(20242CZDX82)
评论